These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 11373787)

  • 1. [Highly active antiretroviral therapy with nevirapine. Therapy compliance determines success].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():64-7. PubMed ID: 11373787
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combined antiretroviral therapy with nevirapine of HIV-infected adults].
    Kravchenko AV
    Ter Arkh; 2004; 76(11):68-71. PubMed ID: 15658542
    [No Abstract]   [Full Text] [Related]  

  • 3. [Reliability: nevirapine. Highly effective + favorable influence on lipid profile].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():42-3. PubMed ID: 16385872
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substituting nevirapine for efavirenz: risk factors for toxicity in nonnaive patients in a resource-constrained setting.
    van Griensven J; Un P; Phe T; Thai S; Lynen L
    AIDS; 2009 Nov; 23(17):2374-6. PubMed ID: 19865033
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
    Manosuthi W; Sungkanuparph S; Thakkinstian A; Rattanasiri S; Chaovavanich A; Prasithsirikul W; Likanonsakul S; Ruxrungtham K
    Clin Infect Dis; 2006 Jul; 43(2):253-5. PubMed ID: 16779754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
    Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
    AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
    Saghayam S; Kumarasamy N; Cecelia AJ; Solomon S; Mayer K; Wanke C
    Clin Infect Dis; 2007 Jan; 44(2):295-300. PubMed ID: 17173234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
    Gil P; de Górgolas M; Estrada V; Arranz A; Rivas P; Yera C; García R; Granizo JJ; Fernández-Guerrero M
    Clin Infect Dis; 2004 Oct; 39(7):1024-9. PubMed ID: 15472856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse interstitial pulmonary opacities induced by nevirapine.
    Sankatsing SU; Schouten WE
    AIDS; 2007 Sep; 21(14):1993-4. PubMed ID: 17721119
    [No Abstract]   [Full Text] [Related]  

  • 11. [Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].
    Tempelman C; Timmermans S; Godfried MH; Dieleman JP; Boer K; van der Ende ME
    Ned Tijdschr Geneeskd; 2004 Oct; 148(41):2021-5. PubMed ID: 15553999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A short-term trial of Didanosine, stavudine, and nevirapine combination therapy for human immunodeficiency virus infection].
    Zheng YH; Yang X; Chang WH
    Hunan Yi Ke Da Xue Xue Bao; 2003 Aug; 28(4):390. PubMed ID: 14653126
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
    Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification.
    Martínez E; Gatell JM
    AIDS; 2007 Aug; 21(13):1829-30. PubMed ID: 17690588
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
    Reliquet V; Allavena C; François-Brunet C; Perré P; Bellein V; Garré M; May T; Souala F; Besnier JM; Raffi F
    HIV Med; 2006 Oct; 7(7):431-6. PubMed ID: 16925728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reliable effectiveness for years with good long-term tolerance: 10 years nevirapine--a summary].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():70. PubMed ID: 19024921
    [No Abstract]   [Full Text] [Related]  

  • 17. Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases and review of the literature.
    Cattelan AM; Trevenzoli M; Sasset L; Sgarabotto D; Lanzafame M; Meneghetti F
    J Infect; 2001 Nov; 43(4):246-9. PubMed ID: 11869062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Researchers examine the benefits of potent antiretroviral therapy and treatment compliance among patients with HIV.
    Insight; 2002; 27(4):115. PubMed ID: 12520987
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.
    van Oosterhout JJ; Bodasing N; Kumwenda JJ; Nyirenda C; Mallewa J; Cleary PR; de Baar MP; Schuurman R; Burger DM; Zijlstra EE
    Trop Med Int Health; 2005 May; 10(5):464-70. PubMed ID: 15860093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Patient-friendly therapy with long-term effectiveness. Once daily HAART is coming].
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():80. PubMed ID: 12043086
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.